Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 24, 2012
Grant Date -
Sep 15, 2011
app pub date -
Jul 19, 2005
filing date -
Jul 20, 2004
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 μM)+QUER(20 μM) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully